1. Home
  2. ACRS vs LPA Comparison

ACRS vs LPA Comparison

Compare ACRS & LPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • LPA
  • Stock Information
  • Founded
  • ACRS 2012
  • LPA 2013
  • Country
  • ACRS United States
  • LPA United States
  • Employees
  • ACRS N/A
  • LPA N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • LPA
  • Sector
  • ACRS Health Care
  • LPA
  • Exchange
  • ACRS Nasdaq
  • LPA Nasdaq
  • Market Cap
  • ACRS 165.7M
  • LPA 196.1M
  • IPO Year
  • ACRS 2015
  • LPA N/A
  • Fundamental
  • Price
  • ACRS $1.80
  • LPA $6.80
  • Analyst Decision
  • ACRS Strong Buy
  • LPA
  • Analyst Count
  • ACRS 9
  • LPA 0
  • Target Price
  • ACRS $9.25
  • LPA N/A
  • AVG Volume (30 Days)
  • ACRS 1.4M
  • LPA 14.8K
  • Earning Date
  • ACRS 08-07-2025
  • LPA 08-13-2025
  • Dividend Yield
  • ACRS N/A
  • LPA N/A
  • EPS Growth
  • ACRS N/A
  • LPA N/A
  • EPS
  • ACRS N/A
  • LPA 0.22
  • Revenue
  • ACRS $16,789,000.00
  • LPA $45,924,457.00
  • Revenue This Year
  • ACRS N/A
  • LPA N/A
  • Revenue Next Year
  • ACRS $8.11
  • LPA N/A
  • P/E Ratio
  • ACRS N/A
  • LPA $30.92
  • Revenue Growth
  • ACRS N/A
  • LPA 6.18
  • 52 Week Low
  • ACRS $1.05
  • LPA $5.71
  • 52 Week High
  • ACRS $5.17
  • LPA $15.85
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 62.45
  • LPA 57.77
  • Support Level
  • ACRS $1.75
  • LPA $5.71
  • Resistance Level
  • ACRS $1.92
  • LPA $6.30
  • Average True Range (ATR)
  • ACRS 0.09
  • LPA 0.38
  • MACD
  • ACRS 0.01
  • LPA 0.05
  • Stochastic Oscillator
  • ACRS 70.00
  • LPA 91.35

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

Share on Social Networks: